Articles related to Cardiology

Atorvastatin reduced major cardiovascular events among adults aged 70 years and older without known cardiovascular disease, diabetes, or dementia, but the benefit did not translate into a statistically significant improvement in disability-free survival over nearly six years of follow-up.

The FDA approved tirzepatide to reduce major cardiovascular event risk in high-risk adults with type 2 diabetes. SURPASS-CVOT established noninferiority to dulaglutide rather than cardiovascular superiority.

Double-filtration plasmapheresis reduced circulating concentrations of several PFAS in small patient samples, while microplastic changes varied by polymer. The exploratory findings do not support apheresis for environmental pollutant removal.

A primary care physician describes combining nutrition counseling, individualized monitoring, and pharmacotherapy in obesity care. The interview offers a practice philosophy rather than comparative evidence supporting one treatment strategy.

Three-year increases or sustained elevations in NT-proBNP were associated with greater cardiovascular and mortality risks among older adults without prior cardiovascular disease. Participants whose elevations resolved had risks resembling those who remained free of heart stress.

A systematic review and meta-analysis found that inclisiran significantly reduced LDL cholesterol compared with placebo across diverse hyperlipidemia populations. Long-term cardiovascular outcome data remain limited despite consistent lipid-lowering efficacy and favorable safety findings.